FDA 483 指出百特 Round Lake 工厂环境监测方法覆盖不足、数据完整性评估未执行
FDA483:百特美国工厂,系统无控制,数据完整性评估未执行,研发执行放行检测无管理
美国 FDA 对百特 Round Lake 工厂(FEI 1416980,委托实验室)2025 年 11 月 17 日至 25 日检查形成的 483 列出五项观察,涉及环境监测方法未覆盖同设施生产的品种、QC 与研发职责未有书面程序界定、研发实验室原始数据可被无审计追踪地修改删除。
本文中观点不代表任何公司和组织,如有觉得有冒犯的地方,请于后台联系,我会及时删除。所有分享案例都具有孤立性,仅供参考。
受检机构/公司:Baxter Healthcare Corporation
城市:Round Lake, IL 60073-9799美国
类型:Contract Laboratory委托实验室
FEI号:1416980
检查员:
Shafiq Ahadi, Investigator
检查日期:2025年11月17日 – 2025年11月25日*
Baxter Healthcare Corporation, Round Lake 工厂,最早是作为 Baxter Healthcare Corp 的 原料药放行检测实验室(Drug Substance Release Tester),为头孢吡肟(Cefepime)注射剂等产品提供检测服务。亦为多款制剂的生产工厂,2026年3月23日–4月2日:FDA对该工厂进行了为期11天的检查,发现严重违反现行药品生产质量管理规范(CGMP)的行为。2026年9月29日:FDA向 Baxter International 发出 警告信(Warning Letter,编号320-26-132)。
DURING AN INSPECTION OF YOUR FIRM I OBSERVED:
【中文译文】在对你企业的检查过程中,我观察到:
观察项 1 / Observation 1
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
【中文译文】实验室控制未包括建立科学合理且适当的检验程序,以确保药品符合鉴别、含量、质量和纯度的相应标准。
Specifically, your firm's environmental monitoring (EM) program for cross-contamination detection has significant limitations in scope and coverage. xxx xxx xxx, are manufactured at your facilities. However, there are no analytical methods for detection of xxx from xxx samples taken from xxx areas. The current test method utilized only detects xxx and fails to include xxx manufactured in the same facility. From January 1, 2025, to November 20, 2025, alone, your firm tested at least xxx EM samples, but only for the presence of xxx. Results for these were found to be false positives for the presence of xxx, and were then subjected to confirmatory testing, xxx xxx (Procedure RD-02-01-020, Document No. 1138932, Revision H) with a concentration limit of xxx xxx for xxx detection.
【中文译文】具体而言,贵公司用于交叉污染检测的环境监测(EM)方案在范围和覆盖面上存在重大局限。xxx xxx xxx 在贵公司设施内生产。然而,贵公司没有分析方法,用于检测取自 xxx 区域的 xxx 样品中的 xxx。目前采用的检验方法仅能检出 xxx,未能涵盖在同一设施内生产的 xxx。仅 2025 年 1 月 1 日至 2025 年 11 月 20 日期间,贵公司就检验了至少 xxx 份环境监测样品,但仅检验其中是否存在 xxx。这些样品的结果被发现为 xxx 检出的假阳性,随后以 xxx xxx(程序 RD-02-01-020,文件编号 1138932,修订版 H)进行确认性检验,该程序就 xxx 检出设有 xxx xxx 的浓度限度。
观察项 2 / Observation 2
The responsibilities and procedures applicable to the quality control unit are not fully followed.
【中文译文】适用于质量控制部门的职责和程序未得到充分遵循。
Specifically,
【中文译文】具体而言,
A.
Risk assessments have failed to adequately evaluate cross-contamination risks in these laboratories where testing occurs for xxx containing products, as follows:
【中文译文】风险评估未能充分评估这些对含 xxx 产品开展检验的实验室的交叉污染风险,具体如下:
The sterility laboratory, located within the xxx building xxx performs both internal and contracted sterility testing for both xxx products.
【中文译文】位于 xxx 楼 xxx 的无菌检查实验室,为各类 xxx 产品同时开展内部及委托无菌检查。
The QC Microbiology Laboratory is located in the xxx section of xxx Building. This laboratory performs both internal and contracted testing, including environmental monitoring and solution bioburden testing, in the same laboratory where xxx samples are also processed.
【中文译文】QC 微生物学实验室位于 xxx 楼的 xxx 区。该实验室在同一实验室内既开展内部及委托检验(包括环境监测与溶液生物负载检验),也处理 xxx 样品。
B.
The oversight by the Quality Control (QC) unit is deficient in that there is no written procedure defining the roles and responsibilities of QC and R&D, including QC's responsibility for reviewing, evaluating, and approving test results generated by R&D laboratories, who perform testing of commercial product. There are xxx R&D personnel who currently execute and approve confirmatory testing for the detection of xxx in environmental samples collected from xxx your own GMP areas, as well those you collect from manufacturing suites of the co-located firm, who manufactures commercial drug product.
【中文译文】质量控制(QC)部门的监督存在缺陷:没有任何书面程序界定 QC 与研发(R&D)的职责范围,包括 QC 对检验商业产品的研发实验室所产生检验结果的审核、评估和批准职责。目前有 xxx 名研发人员执行并批准确认性检验,以检出从 xxx 贵公司自身 GMP 区域,以及从同址企业(该企业生产商业药品)生产车间采集的环境样品中的 xxx。
观察项 3 / Observation 3
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
【中文译文】未对计算机或相关系统实施适当控制,以确保主生产与工艺控制记录或其他记录的变更仅由经授权的人员实施。
Specifically,
【中文译文】具体而言,
A.
xxx The software, xxx that interfaces with the xxx instrument xxx xxx in the R&D laboratory, for the performance of confirmatory testing of "xxx xxx As A Referee Method For Medical Products Procedure RD-02-01-020" for the detection of xxx in environmental samples, is deficient in that the raw data generated and captured can be modified and deleted without administrative-level permissions, audit trails, or electronic records documenting such modification. For example, on November 21, 2025, your R&D personnel demonstrated that the raw data generated from confirmation testing stored in computer folder xxx can be potentially modified and deleted.
【中文译文】A. xxx 与研发实验室中 xxx 仪器 xxx xxx 对接的 xxx 软件,用于依据《xxx xxx 作为医疗器械仲裁检验方法》程序 RD-02-01-020 开展确认性检验,以检出环境样品中的 xxx;该软件存在缺陷:其生成并捕获的原始数据可在没有管理员级权限、审计追踪或记录此类修改的电子记录的情况下被修改和删除。例如,2025 年 11 月 21 日,贵公司研发人员演示了存储在计算机文件夹 xxx 中的确认检验原始数据可被修改和删除。
西门的吐槽:FDA的常见路子,让业务上手去试着删除或者更改,如果成功就是个缺陷
B.
Data integrity gap assessment has not been performed to ensure adequate controls are in place to prevent unauthorized modification or deletion of raw data for the xxx instrument xxx - xxx used to perform confirmatory testing.
【中文译文】B. 尚未开展数据完整性差距评估,以确保对用于开展确认性检验的 xxx 仪器 xxx-xxx 落实适当控制,防止原始数据被未经授权地修改或删除。
西门的吐槽:印象中这不是第一例吐槽百特的DI评估未执行或者执行不当。(如下)FDA检察员跟其他地区检查员不一样的点,有一部分,一上来就问你是否执行过Part11差距分析或者DI评估(我个人碰过俩次,业内也有朋友遇到过检察员直接拿公司的DI自检去确认CAPA是否有效)。这再次作证了我的观点,现在大外资有些时候集团化落地可能存在差异,这里印度的案例可能执行效果不好,但在美国本土却未执行(哪怕是研发实验室,但用于商业化放行检测)
C.
There is no training provided to R&D personnel regarding the handling, storage, and archiving of raw data.
【中文译文】C. 未向研发人员提供有关原始数据处理、存储和归档的培训。
观察项 4 / Observation 4
Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.
【中文译文】从事药品生产和处理的人员缺乏履行其指定职责所需的培训。
Specifically, QC analysts responsible for testing of environmental samples (EM) for the absence of xxx are not trained by the quality team, resulting in inadequate oversight of personnel qualifications. For example, per the firm's training procedure No. RD-03-01-019, Revision W, each analyst is required to complete, including but not limited to, xxx containment training (Training Code: xxx containment training (Training Code: xxx), and good documentation training. QC analysts performing xxx testing have not completed mandatory training requirements per the firm's training procedure (Document No. RD-03-01-019, Revision W).
【中文译文】具体而言,负责环境样品(EM)中 xxx 未检出检验的 QC 分析员未接受质量团队的培训,导致人员资质监督不足。例如,根据公司培训程序 RD-03-01-019(修订版 W),每名分析员须完成(包括但不限于)xxx 密闭防护培训(培训代码:xxx 密闭防护培训(培训代码:xxx)),以及良好文件记录培训。执行 xxx 检验的 QC 分析员尚未按公司培训程序(文件编号 RD-03-01-019,修订版 W)完成强制性培训要求。
观察项 5 / Observation 5
Laboratory records do not include a description of the sample received for testing, the quantity of the sample and the date the sample was received for testing.
【中文译文】实验室记录未包含检验所收样品的描述、样品数量及样品收检日期。
Specifically, your firm does not maintain adequate sample logs for environmental monitoring (EM) samples that failed the absence of xxx test per xxx for Determining the Absence of xxx in Environmental Samples (Document no. RD-02-01-020, Revision S). For example, between January 1 and November 20, 2025, a total of xxx EM samples failed the xxx test for absence of xxx However, there is no record of the receipt and tracking of these samples, which were subjected to xxx Test Method (Procedure RD-02-01-020, Document No. 1138932, Revision H).
【中文译文】具体而言,贵公司未对未通过 xxx 未检出检验的环境监测(EM)样品保持充分的样品台账,该检验依据《xxx 用于判定环境样品中 xxx 未检出》(文件编号 RD-02-01-020,修订版 S)执行。例如,2025 年 1 月 1 日至 11 月 20 日期间,共有 xxx 份环境监测样品未通过 xxx 未检出检验。然而,这些提交 xxx 检验方法(程序 RD-02-01-020,文件编号 1138932,修订版 H)检验的样品,没有任何收检和追踪记录。
来源:BasicPharma搬砖工 · mp.weixin.qq.com